Bronchopulmonary Dysplasia: Myths of Management

Abstract:

Abstract: Bronchopulmonary dysplasia (BPD) is the most common and important respiratory morbidity of prematurity, affecting thousands of infants worldwide annually. In this presentation, I will highlight the significance of BPD from both individual and societal perspectives, discuss the pulmonary injury sequence, and explore the myths of management, including epidemiologic, ventilatory, and pharmacologic aspects. The latter will include diuretics, bronchodilators, corticosteroids, anti-reflux medications, and others, with a review of the available evidence base. A brief look at agents under current investigation will also be provided.

What will audience learn from your presentation?

1. Understand the changing epidemiology of BPD
2. Comprehend the multifactorial bases of the pulmonary injury sequence
3. Realize that infants with BPD are exposed to a myriad of pharmaceutical agents with dubious efficacy and questionable safety.

Biography:

Steven M. Donn, MD, FAAP, FAARC is Professor Emeritus of Pediatrics at the Michigan Medicine and a member of the Division of Neonatal-Perinatal Medicine. Dr. Donn is actively involved in teaching, writing, editing, and clinical research.  He is a member of the SPR, APS, and ESPR, and is internationally known for his expertise in the management of respiratory failure in newborns. He is a Fellow of the American Association for Respiratory Care for his contributions to the profession of respiratory care. He has authored more than 255 articles, written/edited 38 books and specialty journals, and contributed 260 book chapters.